Cortexyme and Sorrento Therapeutics Compared

A side-by-side look at the financial metrics and business profiles of these two biotech companies.

Feb. 23, 2026 at 8:52pm

Got story updates? Submit your updates here. ›

This article provides a comparative analysis of Cortexyme and Sorrento Therapeutics, two clinical-stage biopharmaceutical companies. The comparison covers key financial metrics like net margins, return on equity, and return on assets, as well as top-line revenue, earnings per share, and valuation. The article also examines institutional and insider ownership, stock volatility, and other factors that distinguish the two companies.

Why it matters

This analysis allows investors to better understand the relative strengths and weaknesses of Cortexyme and Sorrento Therapeutics as potential investment opportunities in the biotech sector. It highlights the distinct business profiles, financial performance, and risk profiles of the two companies, which can inform investment decisions.

The details

The article compares Cortexyme and Sorrento Therapeutics across several key metrics. Cortexyme has a higher percentage of institutional ownership at 63.2% compared to Sorrento's 0.0%, indicating stronger backing from large investors. However, Sorrento has a higher percentage of insider ownership at 2.6% versus Cortexyme's 27.9%. Sorrento also has a higher beta of 2.25, suggesting its stock is more volatile than Cortexyme's beta of 1.4. In terms of financial performance, Sorrento outperforms Cortexyme on 6 of the 9 factors compared, including top-line revenue, earnings per share, and valuation.

  • The article was published on February 23, 2026.

The players

Cortexyme, Inc.

A clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.

Sorrento Therapeutics, Inc.

A clinical and commercial stage biopharmaceutical company that develops a portfolio of next-generation treatments for cancer, infectious disease, and pain. It operates through two segments: Sorrento Therapeutics and Scilex.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights the distinct business profiles and financial performance of Cortexyme and Sorrento Therapeutics, two biotech companies with different areas of focus and risk profiles. Investors should carefully consider these factors when evaluating the companies as potential investment opportunities.